Targeting YTHDF2 with an aptamer/liposome containing small interfering RNA effectively inhibits immune escape and blood vessel formation in HCC, causing less harm to normal liver tissue compared to combination therapy. The gene discussed is YTHDF2; the disease is hepatocellular carcinoma.